Stay updated on ZUMA-5 Indolent NHL Clinical Trial
Sign up to get notified when there's something new on the ZUMA-5 Indolent NHL Clinical Trial page.

Latest updates to the ZUMA-5 Indolent NHL Clinical Trial page
- Check4 days agoChange DetectedThe record describes the completed Phase 2 ZUMA-5 study of axicabtagene ciloleucel for relapsed or refractory indolent non-Hodgkin lymphoma, with posted results and details on eligibility, treatment, locations, and publications. It also provides study documents and information about sharing participant data.SummaryDifference79%

- Check11 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA site-wide NIH announcement about a terminology transition appears above the 403 error page. The site revision identifier also changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check39 days agoChange DetectedThe footer revision identifier was updated from v3.7.0 to v3.7.1 while the page continued to display a 403 error.SummaryDifference0.2%

- Check53 days agoChange DetectedA 403 Forbidden error page is now shown for the study record, replacing the expected content and navigation with an access-denied message. This indicates the page is currently inaccessible due to permission restrictions.SummaryDifference20%

- Check60 days agoChange DetectedThe page's revision label was updated from v3.6.6 to v3.7.0, indicating a new version of the page.SummaryDifference0.0%

Stay in the know with updates to ZUMA-5 Indolent NHL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ZUMA-5 Indolent NHL Clinical Trial page.